ReviewAmerican journal of clinical dermatology2022
Evaluating the Longitudinal Course of Atopic Dermatitis: Implications for Clinical Practice.
Review in American journal of clinical dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis.Dermatology and therapy · 2026Article
- Comparative Data on Long-Term Efficacy of Biologics in Moderate-to-Severe AD: An Expert Perspective on Using Indirect Comparison Methodology.Dermatology and therapy · 2026Review
- Characterization of Prurigo Nodules in Adults With Moderate-To-Severe Atopic Dermatitis in Japan: A 2-Year Observational Study.The Journal of dermatology · 2026Observational
- Untangling the Complexity of Childhood Atopic Dermatitis: Phenotypes and Endotypes.Clinical reviews in allergy & immunology · 2026Review
- Secretome as a novel regenerative strategy for atopic dermatitis: a comprehensive review.Stem cell research & therapy · 2026Review
- Short-Term Efficacy of Lebrikizumab Versus Dupilumab in Combination with Topical Corticosteroids in Adults with Moderate-to-Severe Atopic Dermatitis: Matching-Adjusted Indirect Comparison.Dermatology and therapy · 2026Article
- Review
- Incidence and Remission of Atopic Dermatitis in a German Birth Cohort.JAMA network open · 2025Observational
- Defining "Flares" in Atopic Dermatitis: A Narrative Review.American journal of clinical dermatology · 2025Review
- Type 2 Inflammation and Its Role in Dermatologic Diseases.International journal of dermatology · 2025Review
- Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment.Dermatology and therapy · 2024Article
- Abrocitinib may improve itch and quality of life in patients with itch-dominant atopic dermatitis.Skin health and disease · 2024Article
- Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch.Dermatology and therapy · 2024Article
- Atopic March or Atopic Multimorbidity-Overview of Current Research.Medicina (Kaunas, Lithuania) · 2023Review
- Identification of eczema clusters and their association with filaggrin and atopic comorbidities: analysis of five birth cohorts.The British journal of dermatology · 2023Article
- Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids.American journal of clinical dermatology · 2023Review
- Atopic Dermatitis Across Shades of Skin.American journal of clinical dermatology · 2023Review
- Burden of Disease and Unmet Needs in the Diagnosis and Management of Atopic Dermatitis in Korea.Journal of clinical medicine · 2023Review
- Human umbilical cord mesenchymal stem cell treatment alleviates symptoms in an atopic dermatitis-like mouse model.Stem cell research & therapy · 2023Article
- Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Atopic dermatitis (AD) is characterized by a heterogenous longitudinal course with varying severity, flares, and persistence. However, AD course is not routinely assessed in clinical practice or controlled trials. Our objective was to review the longitudinal course of AD in children and adults and discuss implications for routine practice and clinical trials. We conducted a focused review of the published literature, including retrospective, prospective, and interventional studies, clinical trials, and consensus guidelines. Estimates of AD persistence varied widely across studies but suggested that AD can indeed persist through childhood and into adulthood. Predictors of persistence are broad and include both disease-intrinsic and disease-extrinsic (i.e., environmental) factors. In real-world practice, most individuals with AD experience fluctuations in the signs and symptoms over time and do not experience persistent clearance of skin lesions. Clinical trials use mainly static measurements that do not take into account fluctuations in course, which may confound treatment effects. The heterogenous temporal pattern of AD can be incorporated into routine practice to better set expectations and offer a realistic prognosis. AD course should be routinely incorporated into clinical decision making. Future studies are needed to develop a standardized approach to AD assessment and treatment that includes longitudinal course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.